| Literature DB >> 30365567 |
David Sibbritt1, Wenbo Peng1, Romy Lauche1, Caleb Ferguson2, Jane Frawley1, Jon Adams1.
Abstract
BACKGROUND: Modifications to lifestyle risk factors for stroke may help prevent stroke events. This systematic review aimed to identify and summarise the evidence of acupuncture interventions for those people with lifestyle risk factors for stroke, including alcohol-dependence, smoking-dependence, hypertension, and obesity.Entities:
Mesh:
Year: 2018 PMID: 30365567 PMCID: PMC6203376 DOI: 10.1371/journal.pone.0206288
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Search terms for the systematic review.
| Acupuncture treatments | Acupuncture [MeSH Term & Keyword] OR Electroacupuncture [MeSH Term & Keyword] OR Electric stimulation [MeSH Term & Keyword] OR Acupressure [MeSH Term & Keyword] OR Laser acupuncture [MeSH Term & Keyword] OR | |
| AND | ||
| Lifestyle stroke risk factors | High blood pressure | Hypertension [MeSH Term & Keyword] OR Blood pressure [MeSH Terms & Keyword] OR Hypertens |
| High cholesterol | Cholesterol [MeSH Term & Keyword] OR Triglycerides [MeSH Term & Keyword] OR Dyslipidemia [MeSH Term & Keyword] OR Epicholesterol [Title/Abstract] OR HDL [Title/Abstract] OR LDL [Title/Abstract] OR Triglyceride | |
| Obesity | Obesity [MeSH Terms & Keyword] OR Overweight [MeSH Terms & Keyword] OR Metabolic syndrome [MeSH Terms & Keyword] OR Obes | |
| Alcohol-dependence/abuse | Alcohol [MeSH Terms & Keyword] OR Alcohol | |
| Smoking-dependence/abuse | Smoking [MeSH Terms & Keyword] OR Smok | |
| Physical inactivity | Exercise [MeSH Terms & Keyword] OR Exercis | |
* truncation symbol for literature search.
Summary of the included studies.
| Sample | Treatment intervention | Control intervention | Add-on strategy | Results | Side-effects | |
|---|---|---|---|---|---|---|
| Rampes et al. 1997 UK[ | 59 randomized and 27, 26 completed at Wks 8, 24. | Individual alcohol counsellor/group therapy, 6 Wks | Conventional treatment | Alcohol craving: Significant within-group effect—TG1 & TG2 (8Wk) | Drowsiness; transient bleeding on needle removal; pain | |
| TG1: n = 23, 4 F, age 38y; TG2: n = 20, 3 F, age 40y; CG: n = 16, 6 F, age 42y; | ||||||
| Sapir-Weise et al. 1999 Sweden[ | 72 randomized and 72, 59, 51 completed at Wk 10, Mos 3, 6. | Conventional treatment | Drinking days/alcohol craving: NS | N/A | ||
| TG: n = 36, 11 F, age 47y; CG: n = 36, 10 F, age 45y; | ||||||
| Bullock et al. 2002 USA[ | 503 randomized and 356, 289, 247, 220 completed at Wk 3, Mos 3, 6, 12. | Conventional treatment | Alcohol withdrawal symptoms: Significant between-group effect—TG3>TG1 (12-Mo F/U) | N/A | ||
| TG1: n = 132, 65 F, age 39y; TG2: n = 133, 66 F, age 38y; TG3: n = 104, 52 F, age 38y; CG: n = 134, 67 F, age 38 y; | ||||||
| Karst et al. 2002 Germany[ | 34 completed. | Carbamazepine | Alcohol withdrawal symptoms: Significant within-group effect—TG | N/A | ||
| TG: n = 17, 2 F, age 46y; CG: n = 17, 2 F, age 41y; | ||||||
| Trumpler et al. 2003 Switzerland[ | 48 randomized and completed. | Clomethiazole; benzodiazepines if necessary; maintain other drugs before study | Alcohol withdrawal symptoms: NS | Convulsion (TG) | ||
| TG1: | ||||||
| Kunz et al. 2007 Germany[ | 109 randomized and 74 completed. | Carbamazepine or oxcarbazepine; benzodiazepines | Alcohol withdrawal symptoms/alcohol craving: NS | Pain, mild bleeding (TG); agitation, sneezing, sore throat (CG) | ||
| TG: n = 55, 10 F, age 48y; CG: n = 54, 10 F, age 44y; | ||||||
| Lee et al. 2015 Korea[ | 20 randomized and completed. | N/A | Alcohol craving: NS | N/A | ||
| TG: n = 10, age 43y; CG: n = 10, age 45y; | ||||||
| He et al. 1997 Norway[ | 46 randomized (age 39y) and 44, 38, 33 completed at Wk 3, Mo 8, Year 5. | ① | N/A | Daily cigarette consumption, desire to smoke: Significant within-group effect—TG (8-Mo/5-year F/U), CG (8-Mo F/U); Significant between-group effect—TG>CG (8-Mo F/U); | N/A | |
| TG: n = 26, 18 F, age 38y; CG: n = 20, 10 F, age 40y; | Cotinine concentrations: Significant within-group effect—TG; | |||||
| Smoking cessation rate: Significant between-group effect—TG>CG | ||||||
| Waite & Clough 1998 UK[ | 79 randomized and 78 completed at Wk 2, Mos 2, 4, 6. | N/A | Smoking cessation rate: Significant between-group effect—TG>CG (6-Mo F/U) | Soreness, itch, pain of ears (TG); soreness, itch of ears (TG & CG) | ||
| TG: n = 40, 18 F, age 24-67y; CG: n = 38, 16 F, age 23-69y; | ||||||
| White et al. 1998 UK[ | 76 randomized and 52 completed at Wk 2, Mo 9. | N/A | Smoking cessation rate: NS | N/A | ||
| TG: n = 38, 21 F, age 41y; CG: n = 38, 18 F, age 43y; | ||||||
| Georgiou et al. 1998 UK[ | 265 randomized and 216, 175, 63 completed at Wk 1, Mos 1, 3 (age 43y). | N/A | Smoking cessation rate/withdrawal symptoms/craving: NS | N/A | ||
| TG: n = 108; CG: n = 108; | ||||||
| Cai et al. 2000 Singapore[ | 330 randomized and 268 (68 F), 208 completed at 6-session, Mo 3. | N/A | Daily cigarette consumption/Smoking cessation rate: NS | Headache, giddy, nausea, vomiting (TG: 20; CG: 21) | ||
| TG: n = 128; CG: n = 140; | ||||||
| Bier et al. 2002 USA[ | 141 randomized (71 F, age 46y) and 108, 48 completed at Mos 1, 18. | N/A | Daily cigarette consumption, Smoking cessation rate: Significant between-group effect—TG1>CG>TG2 (after treatment) | Minor bleeding on needle removal (both TGs) | ||
| TG1: n = 45; TG2: n = 38; CG: n = 58; | ||||||
| White et al. 2007 UK[ | 24 randomized and 19, 7 completed at Wks 1, 6. | NRT, group behavioral therapy | Withdrawal symptom: NS | N/A | ||
| TG1: n = 6, 2 F, age 51y; TG2: n = 6, 5 F, age 40y; CG: n = 7, 7 F, age 44y; | ||||||
| Wu et al. 2007 Taiwan[ | 118 randomized and completed at Wk 8, Mo 6. | N/A | Withdrawal symptom: Significant within-group effect—TG (after treatment); | Tenderness sensation (n = 50), dizziness (n = 4), minor bleeding (n = 2), nausea sensation (n = 2) | ||
| TG: n = 59, 11 F, age 54y; CG: n = 59, 7 F, age 53y; | Daily cigarette consumption: Significant within-group effect—TG & CG (after treatment) | |||||
| Yeh et al. 2009 Taiwan[ | 79 randomized and 59 completed. | N/A | Daily cigarette consumption: Significant within-group effect—TG & CG | N/A | ||
| TG: n = 30, age 28y; CG: n = 29, age 27y; | ||||||
| Chae et al. 2010 Korea[ | 29 completed. | N/A | Withdrawal symptoms: Significant between-group effect—TG>CG | None | ||
| TG: n = 15; CG: n = 14; | ||||||
| Wing et al. 2010 Hong Kong[ | 70 randomized and 51 completed at Wk 3, Mo 3. | N/A | Daily cigarette consumption: Significant within-group effect—TG (after treatment, 3-Mo F/U), CG (after treatment) | Skin allergy (n = 3) | ||
| TG: n = 38, 12 F, age 47y; CG: n = 32, 9 F, age 46y; | ||||||
| Lambert et al. 2011 Singapore[ | 58 randomized and 55 completed. | N/A | Desire to smoke: Significant between-group effect—TG>both CGs if FTND≥5 | Coughing, giddiness, finger/hand numbness (TG: 9; CG2: 3); runny nose (CG1: 3) | ||
| TG: n = 21, 6 female, age 25y; CG1: n = 20, 7 female, age 24y; CG2: n = 17, 2 female, age 26y; | ||||||
| Fritz et al. 2013 USA[ | 125 randomized and 105 completed. | 1-hour ‘stop-smoking’ class | Daily cigarette consumption, withdrawal symptoms: NS | 15 reported (no detail) | ||
| TG: n = 64, 16 F, age 56y; CG: n = 61, 14 F, age 55y; | ||||||
| Zhang et al. 2013 Australia[ | 43 randomized and 19, 12 completed at Wk 8, Mo 3. | N/A | Daily cigarette consumption, withdrawal symptoms, Smoking cessation rate: NS | Discomfort on ears (TG: 1; CG: 4); Headache, dizziness (CG: 1) | ||
| TG: n = 20; 12 F, age 50y; CG: n = 23; 13 F, age 50y; | ||||||
| Baccetti et al. 2015 Italy[ | 477 randomized and 472, 447, 445 at Wk 5, Mo 6, Year 1. | N/A | Smoking cessation rate: NS | Minor bleeding | ||
| TG1: n = 159, 102 F, age 51y; TG2: n = 162, 103 F, age 50y; CG: n = 156, 100 F, age 48y; | ||||||
| Macklin et al. 2006 USA[ | 192 randomized and 188 completed at Wk 10, Mo 12. | No antihypertensive medications | SBP, DBP: NS | Hypertensive urgencies (TG2: 2); congestive heart failure (CG: 1) | ||
| TG1: n = 64, 30 F, age 57y; TG2: n = 64, 35 F, age 56y; CG: n = 64, 35 F, age 53y; | ||||||
| Flachskampf et al. 2007 Germany[ | 160 randomized and 140, 140, 135, 133 completed at Day 3, Wk 6, Mos 3, 6. | Maintain antihypertensive medication before study | SBP, DBP: Significant within-group effect—TG (after treatment); Significant between-group effect—TG>CG (after treatment, 3-day F/U) | Pain, atrial fibrillation (TG); pain (CG) | ||
| TG: n = 72, 33 F, age 59y; CG: n = 68, 40 F, age 58y; | ||||||
| Yin et al. 2007 Korea[ | 41 randomized and 30 completed. | Maintain antihypertensive medication before study | SBP, DBP: Significant within-group effect—TG; Significant between-group effect—TG>CG (4th-8th Wk) | Bleeding on needle removal (TG: 8) | ||
| TG: n = 15, 11 F; CG: n = 15, 10 F; | ||||||
| Zhang et al. 2008 USA[ | 47 randomized and 45 completed (14 F, age 25y). | N/A | SBP, DBP: Significant within-group effect—TG | N/A | ||
| TG: n = 23; CG: n = 22; | ||||||
| Zhang et al. 2009 USA[ | 27 randomized and completed (age 25y). | Maintain diet, exercise, antihypertensive medications | SBP: Significant within-group effect—TG | N/A | ||
| TG: n = 13; 5 F; CG: n = 14; 5 F; | ||||||
| Kim et al. 2012 Korea[ | 33 randomized and 28 completed. | No antihypertensive medications during the treatment | Nighttime DBP: Significant within-group effect—TG; Significant between-group effect—TG>CG | Slight injection-site pain, small bleeding (TG) | ||
| TG: n = 12; CG: n = 16; | ||||||
| Chen et al. 2013 China[ | 32 randomized and 30 completed (16 F, age 57y). | Maintain antihypertensive medications before study | SBP, DBP: NS | N/A | ||
| TG: n = 15; CG: n = 15; | ||||||
| Sriloy et al. 2015 India[ | 46 randomized and 38 completed. | N/A | DBP: Significant within-group effect—TG; | N/A | ||
| TG: n = 19, 4 F, age 48y; CG: n = 19, 6 F, age 50y; | SBP: Significant within-group effect—CG | |||||
| Li et al. 2015 USA[ | 65 randomized and 64, 20 completed at Wk 8, Mo 3. | N/A | SBP: Significant between-group effect—TG>CG (after treatment, 1-Mo F/U); | None | ||
| TG: n = 33, 17 F, age 58y; CG: n = 32, 18 F, age 54y; | DBP: NS | |||||
| Liu et al. 2015 Korea[ | 30 randomized and 26 completed at Wks 8, 12. | N/A | SBP: Significant within-group effect—TG (after treatment, 4Wk F/U); | None | ||
| TG: n = 15, 12 F, age 49y; CG: n = 15, 11 F, age 53y; | DBP: Significant within-group effect—TG (after treatment); | |||||
| SBP, DBP: Significant between-group effect—TG> CG (after treatment, 4Wk F/U) | ||||||
| Lin et al. 2016 Taiwan[ | 80 randomized and completed. | N/A | SBP, DBP: Significant within-group effect—TG; Significant between-group effect—TG>CG (immediately, 15-/30-min after acupressure) | N/A | ||
| TG: n = 40, 20 F, age 59y; CG: n = 40, 20 F, age 63y; | ||||||
| Zhan et al. 2016 China[ | 174 patients randomized and completed. | N/A | SBP, DBP: Significant within-group effect—TG1 & TG2; Significant between-group effect—TG1>CG; TG2>CG | N/A | ||
| TG1: n = 58, 33 F, age 50y; TG2: n = 58, 31 F, age 50y; CG: n = 58, 34 F, age 50y; | ||||||
| Richards & Marley 1998 Australia[ | 60 randomized and 50 completed. | Maintain diet | Weight loss ≥2kg, suppression of appetite: Significant between-group effect—TG>CG | N/A | ||
| TG: n = 28, age 44y; CG: n = 32, age 43y; | ||||||
| Mazzoni et al. 1999 Italy[ | 40 randomized and 22 completed. | No medications for obesity; restricted saturated fats and snacks; daily abdominal self-massage 30–45 minutes | BMI, suppression of appetite: NS | N/A | ||
| TG: n = 20, 16 F, age 37y; CG: n = 20, 17 F, age 40y; | ||||||
| Wei & Liu 2004 China[ | 195 randomized and completed (187 F, age 36y). | N/A | Weight loss≥3kg: Significant between-group effect—TG>CG1; TG>CG2 | N/A | ||
| TG: n = 76; CG1: n = 64; CG2: n = 55; | ||||||
| Hsu et al. 2005 Taiwan[ | 72 randomized and 63 completed. | Maintain diet | BW, BMI, WC: Significant between-group effect—TG>CG1; TG>CG2 | Mild ecchymosis (n = 3); abdominal discomfort (n = 1) | ||
| TG: n = 22, age 40y; CG1: n = 20, age 41y; CG2: n = 21, age 41y; | ||||||
| Elder et al. 2007 USA[ | 92 randomized and 73 completed. | N/A | Weight loss of 2.8kg: Significant between-group effect—TG2>TG1 | None | ||
| TG1: n = 31, 26 F, age 48y; TG2: n = 30, 27 F, age 48y; CG: n = 31, 26 F, age 46y; | ||||||
| Hsieh 2007 Taiwan[ | 70 randomized and 55 completed. | Education on low-calorie diet; maintain physical activity | BMI: Significant within-group effect—TG | N/A | ||
| TG: n = 27, 24 F; CG: n = 28, 26 F; | ||||||
| Yeh & Yeh 2008 Taiwan[ | 38 randomized and completed. | Maintain diet, physical activity | WC, HC: | None | ||
| TG: n = 19, 16 F, age 33y; CG: n = 19, 16 F, age 33y; | ||||||
| Nourshahi et al. 2009 Iran[ | 27 randomized and completed. | N/A | BMI, fat mass: Significant between-group effect—TG1>CG; TG2>CG | N/A | ||
| TG1: age 42y; TG2: age 40y; CG: age 37y; | ||||||
| Hsu et al. 2009 Taiwan[ | 60 randomized and 45 completed. | Maintain diet | BW, BMI, WC: NS | Minor inflammation (TG: 1); tenderness (TG: 7; CG: 2) | ||
| TG: n = 23, age 40y; CG: n = 22, age 39y; | ||||||
| Hsieh et al. 2010, 2011, 2012 Taiwan[ | 84 randomized and 68 completed. | Education on low-calorie diet; maintain physical activity | BMI: Significant within-group effect—TG1 & TG2; | N/A | ||
| TG1: n = 27, 24 F; TG2: n = 29, 26 F; CG: n = 28, 26 F; | BW, WC: Significant within-group effect—TG1, TG2, & CG; Significant between-group effect—TG2>TG1; | |||||
| Waist-to-hip ratio: Significant within-group effect—TG1 & TG2 | ||||||
| Rerksuppaphol & Rerksuppaphol 2011 Thailand[ | 45 randomized and completed. | Maintain diet, exercise, medication for obesity | Weight loss, BMI: Significant within-group effect—TG | None | ||
| TG: n = 23, age 34y; CG: n = 22, age 33y; | ||||||
| Rerksuppaphol 2012 Thailand[ | 40 randomized and 29 completed. | Maintain diet, exercise | BW, BMI, WC, waist-to-hip ratio: Significant within-group effect—TG; | N/A | ||
| TG: n = 20, age 41y; CG: n = 20, age 32y; | BW, BMI: Significant between-group effect—TG>CG | |||||
| Lien et al. 2012 Taiwan[ | 90 randomized and 71 completed. | Maintain diet, lifestyle | BW, BMI, WC: Significant within-group effect—TG1 & TG2 | Dizziness (TG1: 1). | ||
| TG1: n = 24, age 39y; TG2: n = 24, age 42y; CG: n = 23, age 41y; | ||||||
| Darbandi et al. 2012 Iran[ | 90 randomized and 86, 84 completed at Wk 6, Mo 2. | Low-calorie diet | BW, BMI: Significant within-group effect—TG & CG (after treatment) | None | ||
| TG: n = 43, 37 F, age 38y; CG: n = 43, 37 F, age 38y; | ||||||
| Abdi et al. 2012 Iran[ | 196 randomized and 161 completed at Wks 6, 12. | Low-calorie diet | BW, BMI, HC: Significant within-group effect—TG & CG (after treatment, 6Wk F/U); | None | ||
| TG: n = 79, age 37y; CG: n = 82, age 37y; | WC: Significant within-group effect—TG (after treatment, 6Wk F/U), CG (after treatment) | |||||
| He et al. 2012 China[ | 60 randomized and completed (age 34y). | Low-calorie diet; no food after 8PM | BW, BMI, WC: Significant within-group effect—TG & CG; | N/A | ||
| TG: n = 30; CG: n = 30; | BW: Significant between-group effect—TG>CG | |||||
| Guo et al. 2014 China[ | 64 randomized and 61 completed (32 F, age 37y). | N/A | BW: Significant within-group effect—TG & CG | N/A | ||
| TG: n = 32; CG: n = 32; | ||||||
| Wu et al. 2014 China[ | 72 randomized and 65 completed. | N/A | BW, BMI, WC, HC: Significant within-group effect—TG & CG | N/A | ||
| TG: n = 36, age 28y; CG: n = 36, age 28y; | ||||||
| Kim et al. 2014 Korea[ | 58 randomized and 49 completed. | No information | N/A | BW, BMI: Significant within-group effect—TG & CG; Significant between-group effect—TG>CG | N/A | |
| TG: n = 25, age 21y; CG: n = 24, age 21y; | ||||||
| Yeo et al. 2014 Korea[ | 91 randomized and 58 completed. | Low-calorie diet; no extra exercise | BW, BMI: Significant between-group effect—TG1>CG; TG2>CG; | N/A | ||
| TG1: n = 31, 25 F, age 35y; TG2: n = 30, 25 F, age 39y; CG: n = 30, 25 F, age 43y; | WC: Significant between-group effect—TG1>CG | |||||
| Schukro et al. 2014 Austria[ | 56 randomized and 45, 42 completed at Wks 6, 10. | N/A | BW, BMI: Significant between-group effect—TG>CG (after treatment, 4Wk F/U) | Skin irritations (n = 8) | ||
| TG: n = 28, age 54y; CG: n = 28, age 50y; | ||||||
| Darbandi et al. 2014 Iran[ | 80 randomized and completed. | Low-calorie diet | BMI: Significant between-group effect—TG1>CGs1, 2; TG2>CGs1, 2; | None | ||
| TG1: n = 20, age 38y; TG2: n = 20, age 39y; CG1: n = 20, age 38y; CG2: n = 20, age 38y; | HC: Significant between-group effect—TG1>CGs1, 2; TG2>CGs1, 2; TG2>TG1; | |||||
| WC: Significant between-group effect—TG1>CGs1, 2; TG2>CG2; TG1>TG2 | ||||||
| Yeh et al. 2015 Taiwan[ | 134 randomized and 70 completed (35 F). | Nutrition counselling | BMI: Significant within-group effect—TG & CG | N/A | ||
| TG: n = 36, age 30y; CG: n = 34, age 33y; | ||||||
| He et al. 2015 China[ | 56 randomized and completed. | Maintain diet; no physical training or exercise | BW, BMI: Significant within-group effect—TG & CG | N/A | ||
| Jiao et al. 2015 China[ | 48 randomized and completed. | No overeating | Fat mass: NS | N/A | ||
| TG: n = 24, age 35y; CG: n = 24, age 36y; | ||||||
aAdd-on strategy of all the intervention groups.
Wk: Week; TG: treatment group; CG: Control group; F: Female; Age, mean age; Mo: Month; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders IIIR; NS, not statistically significant; N/A, not available; F/U: follow-up; ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders 4thed; NRT, nicotine replacement therapy; FTND, Fagerstrom Test for Nicotine Dependence; TEAS, transcutaneous electric acupoint stimulation; PHQ-9, 9-item Patient Health Questionnaire; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; BW, body weight; BMI, body mass index; WC, waist circumference; HC, hip circumference; M: male.
Effect sizes of acupuncture in comparison to sham acupuncture or no treatment.
| Outcome | RCT number | Participant number | Heterogeneity | Subgroup difference | p | |
|---|---|---|---|---|---|---|
| Experimental group | Control group | |||||
| Smoking-dependence risk factor—Daily cigarette consumption | ||||||
| Acupressure VS Sham intervention | 2 [36,37] | 58 | 55 | 0%;0.45;0.50 | MD = -2.75 cigarette/day (-5.33, -0.17) | 0.04 |
| Smoking-dependence risk factor—Smoking withdrawal symptoms | ||||||
| Acupuncture VS Sham intervention | 3 [26,33,35] | 89 | 89 | 90%;19.8;<0.001 | SMD = -0.95 (-2.17,0.26) | 0.12 |
| Smoking-dependence risk factor—Smoking cessation rate (short-term) | ||||||
| Acupuncture VS Sham intervention | 3 [26,27,33] | 205 | 205 | 0%;0.70;0.71 | RR = 1.11 (0.85, 1.46) | 0.44 |
| Acupressure VS Sham intervention | 2 [36,37] | 58 | 55 | 0%;0.19;0.66 | RR = 0.39 (0.08, 1.96) | 0.26 |
| Acupuncture plus acupressure VS Sham intervention | 2 [23/24,38] | 179 | 180 | 66%;2.96;0.09 | RR = 2.51 (0.26, 24.24) | 0.43 |
| Smoking-dependence risk factor—Smoking cessation rate (long-term) | ||||||
| Acupuncture VS Sham intervention | 2 [26,33] | 51 | 49 | 0%;0.52;0.47 | RR = 1.13 (0.40, 3.21) | 0.82 |
| Acupressure VS Sham intervention | 2 [36,37] | 49 | 40 | 0%;0;0.95 | RR = 2.43 (0.40, 14.66) | 0.33 |
| Acupuncture plus acupressure VS Sham intervention | 2 [24,38] | 164 | 170 | 22%;1.28;0.26 | RR = 1.97 (0.67, 5.80) | 0.22 |
| Hypertension risk factor—Systolic blood pressure | ||||||
| Acupuncture VS Sham intervention | 2 [40,48] | 84 | 84 | 78%;4.59;0.03 | MD = -0.54 mmHg (-10.69, 9.60) | 0.92 |
| Hypertension risk factor—Diastolic blood pressure | ||||||
| Acupuncture VS Sham intervention | 2 [40,48] | 84 | 84 | 0%;0.89;0.35 | MD = -1.38 mmHg (-4.06, 1.31) | 0.32 |
| Obesity risk factor—Body weight | ||||||
| Acupuncture VS No treatment | 2 [54,69] | 54 | 53 | 50%;1.99;0.16 | MD = -1.12 kg (-5.51, 3.27) | 0.62 |
| Acupressure VS No treatment | 2 [57,71] | 44 | 43 | 32%;1.47;0.23 | MD = -2.87 kg (-6.47, 0.74) | 0.12 |
| Acupuncture VS Sham intervention | 4 [59,64,67,72] | 157 | 157 | 0%;0.73;0.87 | MD = -2.66 kg (-6.05, 0.72) | 0.12 |
| Acupressure VS Sham intervention | 2 [64,66] | 67 | 66 | 0%;0.41;0.52 | MD = -1.01 kg (-4.55, 2.52) | 0.57 |
| Obesity risk factor—Body mass index | ||||||
| Acupressure VS No treatment | 2 [57,71] | 44 | 43 | 49%;1.95;0.16 | MD = -0.41 kg/m2 (-1.56, 0.73) | 0.48 |
| Acupuncture VS Sham intervention | 5 [59,64,67,72,74] | 177 | 177 | 18%;4.88;0.30 | MD = 0.12 kg/m2 (-0.88, 1.13) | 0.81 |
| Acupressure VS Sham intervention | 2 [64,66] | 67 | 66 | 0%;0.26;0.61 | MD = -0.44 kg/m2 (-1.65, 0.78) | 0.48 |
| Obesity risk factor—Waist circumference | ||||||
| Acupuncture VS Sham intervention | 5 [59,64,67,72,74] | 177 | 177 | 0%;1.61;0.81 | MD = -2.79 cm (-4.13, -1.46) | <0.001 |
aMD: Mean difference. SMD: standardized mean difference; RR: risk ratio; I2: the percentage of variation across studies that is due to heterogeneity; Chi2: chi-square test.
Risk of bias of the included studies using the Cochrane Risk of Bias Tool.
| Reference | Risk factor | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias |
|---|---|---|---|---|---|---|---|---|
| Rampes et al., 1997, UK [ | Alcohol | Low risk | Low risk | High risk | Low risk | Low risk | Low risk | Low risk |
| Sapir-Weise et al., 1999, Sweden [ | Alcohol | Unclear | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear |
| Bullock et al., 2002, USA [ | Alcohol | Low risk | High risk | High risk | Low risk | High risk | Low risk | Unclear |
| Karst et al., 2002, Germany [ | Alcohol | Unclear | Unclear | Low risk | Low risk | Unclear | Low risk | Unclear |
| Trumpler et al., 2003, Switzerland [ | Alcohol | Low risk | Low risk | High risk | Low risk | Low risk | Low risk | High risk |
| Kunz et al., 2007, Germany [ | Alcohol | Unclear | Unclear | High risk | Unclear | High risk | Low risk | High risk |
| Lee et al., 2015, Korea [ | Alcohol | Low risk | High risk | Low risk | Low risk | Low risk | Low risk | Unclear |
| He et al., 1997, Norway [ | Smoking | Low risk | High risk | Low risk | Unclear | Low risk | Low risk | Low risk |
| Waite & Clough, 1998, UK [ | Smoking | Unclear | Unclear | Low risk | Unclear | High risk | Low risk | Low risk |
| White et al., 1998, UK [ | Smoking | Low risk | Low risk | Low risk | Low risk | High risk | Low risk | Low risk |
| Georgiou et al., 1998, UK [ | Smoking | Low risk | High risk | High risk | Low risk | High risk | Low risk | Low risk |
| Cai et al., 2000, Singapore [ | Smoking | Low risk | High risk | Low risk | Low risk | High risk | Low risk | Low risk |
| Bier et al., 2002, USA [ | Smoking | Low risk | High risk | Low risk | Low risk | High risk | High risk | Low risk |
| White et al., 2007, UK [ | Smoking | Low risk | Low risk | High risk | High risk | High risk | Low risk | Unclear |
| Wu et al., 2007, Taiwan [ | Smoking | Low risk | High risk | Unclear | Unclear | Low risk | Low risk | High risk |
| Yeh et al., 2009, Taiwan [ | Smoking | Unclear | Unclear | Unclear | Unclear | Unclear | High risk | Low risk |
| Chae et al., 2010, Korea [ | Smoking | Low risk | High risk | Unclear | Unclear | Unclear | Low risk | Low risk |
| Wing et al., 2010, Hong Kong [ | Smoking | Low risk | High risk | Unclear | Unclear | High risk | Low risk | Low risk |
| Lambert et al., 2011, Singapore [ | Smoking | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Fritz et al., 2013, USA [ | Smoking | Low risk | Low risk | High risk | Low risk | High risk | Low risk | Low risk |
| Zhang et al., 2013, Australia [ | Smoking | Low risk | Low risk | Low risk | Low risk | High risk | Low risk | Low risk |
| Baccetti et al., 2015, Italy [ | Smoking | Low risk | High risk | Unclear | Unclear | High risk | Low risk | High risk |
| Macklin et al., 2006, USA [ | Hypertension | Low risk | low risk | Low risk | Unclear | Low risk | Low risk | High risk |
| Flachskampf et al., 2007, Germany [ | Hypertension | Low risk | Low risk | Low risk | Unclear | Low risk | Low risk | Unclear |
| Yin et al., 2007, Korea [ | Hypertension | Low risk | High risk | Low risk | Low risk | High risk | Low risk | Low risk |
| Zhang et al., 2008, USA [ | Hypertension | Low risk | High risk | Low risk | Unclear | Low risk | Low risk | Unclear |
| Zhang et al., 2009, USA [ | Hypertension | Low risk | High risk | High risk | Low risk | Low risk | Low risk | High risk |
| Kim et al., 2012, Korea [ | Hypertension | Low risk | Low risk | Low risk | Low risk | High risk | Low risk | Unclear |
| Chen et al., 2013, China [ | Hypertension | Unclear | Unclear | High risk | Unclear | Unclear | High risk | Unclear |
| Sriloy et al., 2015, India [ | Hypertension | Unclear | Low risk | High risk | Unclear | High risk | High risk | High risk |
| Li et al., 2015, USA [ | Hypertension | Low risk | High risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Liu et al., 2015, Korea [ | Hypertension | Low risk | Low risk | High risk | Low risk | Low risk | Low risk | High risk |
| Lin et al., 2016, Taiwan [ | Hypertension | Low risk | Low risk | Unclear | Unclear | Low risk | Low risk | High risk |
| Zhan et al., 2016, China [ | Hypertension | Low risk | High risk | High risk | Unclear | Low risk | Low risk | Unclear |
| Richards & Marley, 1998, Australia [ | Obesity | Low risk | High risk | High risk | Unclear | High risk | Low risk | Low risk |
| Mazzoni et al., 1999, Italy [ | Obesity | Unclear | Unclear | High risk | Low risk | High risk | Low risk | Low risk |
| Wei & Liu, 2004, China [ | Obesity | Unclear | Unclear | High risk | Unclear | Low risk | Unclear | Unclear |
| Hsu et al., 2005, Taiwan [ | Obesity | Low risk | High risk | High risk | Unclear | Low risk | Low risk | Low risk |
| Elder et al., 2007, USA [ | Obesity | Unclear | Unclear | High risk | Low risk | High risk | High risk | Low risk |
| Hsieh, 2007, Taiwan [ | Obesity | Unclear | Unclear | Unclear | Unclear | High risk | Low risk | Unclear |
| Yeh & Yeh, 2008, Taiwan [ | Obesity | Low risk | High risk | High risk | High risk | Low risk | Low risk | High risk |
| Nourshahi et al., 2009, Iran [ | Obesity | Unclear | Unclear | High risk | Unclear | Low risk | Low risk | Unclear |
| Hsu et al., 2009, Taiwan [ | Obesity | Low risk | High risk | Low risk | Unclear | High risk | Low risk | Low risk |
| Hsieh, 2010, Taiwan [ | Obesity | Unclear | Unclear | Unclear | Unclear | High risk | High risk | High risk |
| Rerksuppaphol & Rerksuppaphol, 2011, Thailand [ | Obesity | Low risk | High risk | High risk | High risk | Low risk | Low risk | Low risk |
| Rerksuppaphol, 2012, Thailand [ | Obesity | Low risk | High risk | High risk | Unclear | High risk | Low risk | High risk |
| Lien et al., 2012, Taiwan [ | Obesity | Low risk | High risk | Low risk | Unclear | High risk | Low risk | Low risk |
| Darbandi et al., 2012, Iran [ | Obesity | Low risk | High risk | Unclear | Unclear | Low risk | Low risk | Low risk |
| Abdi et al., 2012, Iran [ | Obesity | Unclear | Unclear | Unclear | Unclear | High risk | Low risk | Low risk |
| He et al., 2012, China [ | Obesity | Unclear | Unclear | High risk | Unclear | Low risk | Low risk | High risk |
| Guo et al., 2014, China [ | Obesity | Unclear | Unclear | High risk | Unclear | Low risk | Low risk | High risk |
| Wu et al., 2014, China [ | Obesity | Low risk | High risk | Low risk | Unclear | Low risk | Low risk | High risk |
| Kim et al., 2014, Korea [ | Obesity | Low risk | High risk | High risk | Unclear | High risk | Low risk | Low risk |
| Yeo et al., 2014, Korea [ | Obesity | Low risk | Low risk | High risk | Unclear | High risk | Low risk | High risk |
| Schukro et al., 2014, Austria [ | Obesity | Low risk | High risk | High risk | Unclear | High risk | Low risk | Low risk |
| Darbandi et al., 2014, Iran [ | Obesity | Low risk | High risk | High risk | High risk | Low risk | Low risk | Low risk |
| Yeh et al., 2015, Taiwan [ | Obesity | Low risk | Low risk | low risk | Unclear | High risk | Low risk | High risk |
| He et al., 2015, China [ | Obesity | Low risk | High risk | High risk | Unclear | Low risk | Low risk | High risk |
| Jiao et al., 2015, China [ | Obesity | Low risk | High risk | High risk | Unclear | Low risk | Unclear | Unclear |
aBlinding of participants and personnel: We only focus upon the blinding of participants as blinding the acupuncturists in acupuncture treatments is impossible due to methodological reasons.
Fig 1PRISMA flowchart of literature search and study selection.